Menopausal Symptoms and Bone Health in Women Undertaking Risk Reducing Bilateral Salpingo-oophorectomy: Significant Bone Health Issues in Those Not Taking HRT

Overview

Journal Br J Cancer

Specialty Oncology

Date 2011 Jun 10

PMID 21654687

Citations 21

Authors

J Challberg

L Ashcroft

F Lalloo

B Eckersley

R Clayton

P Hopwood

P Selby

A Howell

D G Evans

Affiliations

Soon will be listed here.

Abstract

Background: Women at high ovarian cancer risk, especially those with mutations in BRCA1/BRCA2, are encouraged to undergo bilateral risk-reducing salpingo-oophorectomy (BRRSPO) prior to the natural menopause. The decision to use HRT to cover the period of oestrogen deprivation up to 50 years of age is difficult because of balancing the considerations of breast cancer risk, bone and cardiovascular health.

Methods: We reviewed by questionnaire 289 women after BRRSPO aged ≤48 years because of high ovarian cancer risk; 212 (73%) of women responded.

Results: Previous HRT users (n=67) had significantly worse endocrine symptom scores than 67 current users (P=0.006). A total of 123 (58%) of women had ≥24 months of oestrogen deprivation <50 years with 78 (37%) never taking HRT. Bone density (DXA) evaluations were available on 119 (56%) women: bone loss with a T score of ≤-1.0 was present in 5 out of 31 (16%) women with no period of oestrogen deprivation <50 years compared with 37 out of 78 (47%) of those with ≥24 months of oestrogen deprivation (P=0.03).

Interpretation: Women undergoing BRRSPO <50 years should be counselled concerning the risks/benefits of HRT, taking into consideration the benefits on symptoms, bone health and cardiovascular health, and that the risks of breast cancer from oestrogen-only HRT appear to be relatively small.

Citing Articles

The risk of endocrine interventions in carriers of a genetic predisposition for breast and gynecologic cancers: recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer.

Ortmann O, Schuler-Toprak S, Kast K J Cancer Res Clin Oncol. 2024; 150(9):417.

PMID: 39259360 PMC: 11390776. DOI: 10.1007/s00432-024-05936-7.

Interindividual differences contribute to variation in microbiota composition more than hormonal status: A prospective study.

Jackova Z, Stepan J, Coufal S, Kostovcik M, Galanova N, Reiss Z Front Endocrinol (Lausanne). 2023; 14:1139056.

PMID: 37033235 PMC: 10081494. DOI: 10.3389/fendo.2023.1139056.

Hysterectomy, bilateral oophorectomy, and breast cancer risk in a racially diverse prospective cohort study.

Lovett S, Sandler D, OBrien K J Natl Cancer Inst. 2023; 115(6):662-670.

PMID: 36806439 PMC: 10248837. DOI: 10.1093/jnci/djad038.

Long-Term Non-Cancer Risks in People with Mutations following Risk-Reducing Bilateral Salpingo-Oophorectomy and the Role of Hormone Replacement Therapy: A Review.

Nitschke A, do Valle H, Dawson L, Kwon J, Hanley G Cancers (Basel). 2023; 15(3).

PMID: 36765666 PMC: 9913268. DOI: 10.3390/cancers15030711.

Loss of bone density and bone strength following premenopausal risk-reducing bilateral salpingo-oophorectomy: a prospective controlled study (WHAM Study).

Jiang H, Robinson D, Lee P, Krejany E, Yates C, Hickey M Osteoporos Int. 2020; 32(1):101-112.

PMID: 32856124 DOI: 10.1007/s00198-020-05608-5.

References

. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994; 843:1-129. View

Whittemore A, Gong G, Itnyre J . Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet. 1997; 60(3):496-504. PMC: 1712497. View

Beral V . Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003; 362(9382):419-27. DOI: 10.1016/s0140-6736(03)14065-2. View

Hermsen B, Olivier R, Verheijen R, van Beurden M, de Hullu J, Massuger L . No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer. 2007; 96(9):1335-42. PMC: 2360170. DOI: 10.1038/sj.bjc.6603725. View

Armstrong K, Schwartz J, Randall T, Rubin S, Weber B . Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J Clin Oncol. 2004; 22(6):1045-54. DOI: 10.1200/JCO.2004.06.090. View

Rivera C, Grossardt B, Rhodes D, Brown Jr R, Roger V, Melton 3rd L . Increased cardiovascular mortality after early bilateral oophorectomy. Menopause. 2008; 16(1):15-23. PMC: 2755630. DOI: 10.1097/gme.0b013e31818888f7. View

Shuster L, Rhodes D, Gostout B, Grossardt B, Rocca W . Premature menopause or early menopause: long-term health consequences. Maturitas. 2009; 65(2):161-6. PMC: 2815011. DOI: 10.1016/j.maturitas.2009.08.003. View

Cummings S, Browner W, Bauer D, Stone K, Ensrud K, Jamal S . Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med. 1998; 339(11):733-8. DOI: 10.1056/NEJM199809103391104. View

Beral V, Reeves G, Bull D, Green J . Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst. 2011; 103(4):296-305. PMC: 3039726. DOI: 10.1093/jnci/djq527. View

10.

Gallicchio L, Whiteman M, Tomic D, Miller K, Langenberg P, Flaws J . Type of menopause, patterns of hormone therapy use, and hot flashes. Fertil Steril. 2006; 85(5):1432-40. DOI: 10.1016/j.fertnstert.2005.10.033. View

11.

Jones K, Ravnikar V, Tulchinsky D, SCHIFF I . Comparison of bone density in amenorrheic women due to athletics, weight loss, and premature menopause. Obstet Gynecol. 1985; 66(1):5-8. View

12.

Rebbeck T, Lynch H, Neuhausen S, Narod S, Veer L, Garber J . Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002; 346(21):1616-22. DOI: 10.1056/NEJMoa012158. View

13.

Ewertz M, Mellemkjaer L, Poulsen A, Friis S, Sorensen H, Pedersen L . Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. Br J Cancer. 2005; 92(7):1293-7. PMC: 2361963. DOI: 10.1038/sj.bjc.6602472. View

14.

Evans D, Gaarenstroom K, Stirling D, Shenton A, Maehle L, Dorum A . Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet. 2008; 46(9):593-7. DOI: 10.1136/jmg.2008.058248. View

15.

van der Voort D, van Der Weijer P, Barentsen R . Early menopause: increased fracture risk at older age. Osteoporos Int. 2003; 14(6):525-30. DOI: 10.1007/s00198-003-1408-1. View

16.

Salpeter S, Cheng J, Thabane L, Buckley N, Salpeter E . Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am J Med. 2009; 122(11):1016-1022.e1. DOI: 10.1016/j.amjmed.2009.05.021. View

17.

Evans D, Shenton A, Woodward E, Lalloo F, Howell A, Maher E . Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer. 2008; 8:155. PMC: 2447846. DOI: 10.1186/1471-2407-8-155. View

18.

Fallowfield L, Leaity S, Howell A, Benson S, Cella D . Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat. 1999; 55(2):189-99. DOI: 10.1023/a:1006263818115. View

19.

Howell A, Evans G . Hormone replacement therapy and breast cancer. Recent Results Cancer Res. 2011; 188:115-24. DOI: 10.1007/978-3-642-10858-7_10. View

20.

Oei A, Massuger L, Bulten J, Ligtenberg M, Hoogerbrugge N, de Hullu J . Surveillance of women at high risk for hereditary ovarian cancer is inefficient. Br J Cancer. 2006; 94(6):814-9. PMC: 2361371. DOI: 10.1038/sj.bjc.6603015. View